MedTrace Logo

Levodopa for Diabetic Retinopathy

NCT07444892 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2026-03-03

No results posted yet for this study

Summary

The purpose of this study is to determine optimum dosing strategies of levodopa and determine the physiologic mechanisms that provide the therapeutic response to restore abnormalities in the electrical conductivity of the retina in people with diabetes and no clinically visible retinopathy.

Conditions

Interventions

DRUG

Levodopa

Patients will receive tablets of generic 25 mg carbidopa/100 mg levodopa as the drug treatment.

DRUG

Placebo

Patients will receive matching placebo tablets as the drug treatment.

Sponsors & Collaborators

  • Morningside Center for Innovative and Affordable Medicine

    collaborator UNKNOWN

  • Emory University

    lead OTHER

Principal Investigators

  • Andrew Hendrick, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-18
Primary Completion
2025-11-17
Completion
2025-11-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07444892 on ClinicalTrials.gov